Literature DB >> 18194958

In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves.

Yan Li1, Shujuan Sun, Qiongjie Guo, Lin Ma, Changwen Shi, Lequn Su, Hongjian Li.   

Abstract

OBJECTIVES: To investigate the in vitro interaction between three azoles (fluconazole, itraconazole and voriconazole) and cyclosporin A against five azole-susceptible (azole-S) and five azole-resistant (azole-R) clinical Candida albicans isolates.
METHODS: By using a chequerboard technique and time-kill curves, synergistic, indifferent or antagonistic effects when drugs were used in combination were assessed. In the chequerboard assay, the antifungal activity of drug combinations was determined by the microdilution method based on the CLSI M27-A2 guidelines. The effects of the interactions were assessed by two non-parametric approaches (fractional inhibitory concentration index model and deltaE model). In the time-kill assay, a colony counting method was employed against one azole-S strain and one azole-R strain at 0, 6, 12, 24 and 48 h of incubation at 35 degrees C.
RESULTS: Good concordance was found between the chequerboard method and time-kill curves. Indifference or synergism was observed for azole-S isolates in interactions of azoles and cyclosporin A, while strong synergism was observed for azole-R isolates in all drug combinations.
CONCLUSIONS: Cyclosporin A showed potent synergism when combined with the three azoles, especially against azole-R C. albicans strains, and there was good agreement between various methods used in this study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18194958     DOI: 10.1093/jac/dkm493

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

Authors:  Eric Dannaoui; Patrick Schwarz; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

2.  In vitro interaction between fluconazole and triclosan against clinical isolates of fluconazole-resistant Candida albicans determined by different methods.

Authors:  Lu Yu; Guanghui Ling; Xuming Deng; Jing Jin; Qi Jin; Na Guo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 3.  Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity.

Authors:  Gina Wall; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  Azole-synergistic anti-candidal activity of altenusin, a biphenyl metabolite of the endophytic fungus Alternaria alternata isolated from Terminalia chebula Retz.

Authors:  Jatuporn Phaopongthai; Suthep Wiyakrutta; Duangdeun Meksuriyen; Nongluksna Sriubolmas; Khanit Suwanborirux
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

5.  Comparison of microplate and macrodilution methods in time-kill study of new antimicrobial drugs.

Authors:  Ying Zhou; Zheng Hou; Chao Fang; Xiaoyan Xue; Fei Da; Yukun Wang; Hui Bai; Xiaoxing Luo
Journal:  Folia Microbiol (Praha)       Date:  2012-06-09       Impact factor: 2.099

6.  Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Authors:  April C Joice; Sihyung Yang; Abdelbasset A Farahat; Heidi Meeds; Mei Feng; Junan Li; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.

Authors:  Lingmei Sun; Shujuan Sun; Aixia Cheng; Xiuzhen Wu; Yu Zhang; Hongxiang Lou
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  Antifungal activity of geldanamycin alone or in combination with fluconazole against Candida species.

Authors:  Jinqing Zhang; Wei Liu; Jingwen Tan; Yi Sun; Zhe Wan; Ruoyu Li
Journal:  Mycopathologia       Date:  2013-01-23       Impact factor: 2.574

9.  Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

Authors:  M A Pfaller; S A Messer; N Georgopapadakou; L A Martell; J M Besterman; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

10.  Characterization of the transcriptional response of Candida parapsilosis to the antifungal peptide MAF-1A.

Authors:  Rong Cheng; Wei Li; Klarke M Sample; Qiang Xu; Lin Liu; Fuxun Yu; Yingjie Nie; Xiangyan Zhang; Zhenhua Luo
Journal:  PeerJ       Date:  2020-09-07       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.